This article was published in the Dystonia Dialogue. Botulinum neurotoxin (BNT) therapy is one of the most common treatments to reduce dystonia symptoms. BNT therapy involves injecting appropriate doses of BNT into the appropriate selection of muscles. Both the muscles to be treated and the specific doses determine the dosing regimen for an individual patient. […]
Botulinum neurotoxin (BNT) injections are a common treatment for dystonia. This therapy is used to treat dystonia symptoms in a specific group of muscles, for example, the neck, face, or a limb. Despite the popularity of this treatment for dystonia, certain important aspects of the therapy may come as a surprise to new patients. BNT […]
This article was originally published in the Dystonia Dialogue. The Covid-19 outbreak has had a disproportionate impact on individuals with disabilities and chronic medical conditions, including those with dystonia. There has been widespread disruption of local public services, delays in treatment appointments, and changes to everyday routines. The DMRF checked in with several members of […]
The US Food & Drug Administration (FDA) has approved the use of the botulinum neurotoxin Xeomin® (incobotulinumtoxinA) as a first-line treatment of blepharospasm in adults, as announced in a press release from Merz. Blepharospasm is a focal dystonia that causes muscles around the eyes to contract involuntarily. Individuals with blepharospasm may experience excessive blinking, light […]
We need your valuable input. Please consider participating in a brief, anonymous survey to help the Dystonia Medical Research Foundation better understand your experiences with botulinum neurotoxin injections. Individuals who are diagnosed with dystonia and receive treatment in the USA are welcome to participate. Click here to participate. Any questions, please contact us.